›› 2010, Vol. 30 ›› Issue (3): 249-.

• Monographic report (Radionuclide therapy for thyroid carcinoma) • Previous Articles     Next Articles

Analysis of influential factors for efficacy of 131I thyroid remnant ablation for differentiated thyroid carcinoma

FU Hong-liang, DU Xue-liang, GU Zhen-hui, ZOU Ren-jian, WU Zhen, WANG Hui   

  1. Department of Nuclear Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
  • Online:2010-03-25 Published:2010-03-24
  • Supported by:

    Shanghai Leading Academic Discipline Project, S30203

Abstract:

Objective To analyse the influential factors for efficacy of radioiodine (131I) thyroid remnant ablation for differentiated thyroid carcinoma (DTC) after operation. Methods The clinical data of patients undergoing 131I thyroid remnant ablation after operation for DTC were collected. Binary Logistic regression analysis and chi-square test were employed to analyse the effects of gender, age, pathologic type, metastasis, volume of thyroid remnant tissues, serum thyroidstimulating hormone (TSH) level, rate of thyroid iodine uptake and 131I ablative dose on efficacy of thyroid remnant ablation. Results The clinical data of 183 patients were collected, among whom 109 (59.56%) achieved successful thyroid remnant ablation at first dose. Binary Logistic regression analysis indicated that the volume of thyroid residue and ablative dose of 131I were the main factors for the efficacy of ablation (Wald=8.59, P=0.003; Wald=6.40, P=0.011). Chi-square test revealed that the ablation efficacy in patients with TSH≥30 μIU/mL was higher than that in those with TSH<30 μIU/mL (χ2=7.291, P=0.007), while there was no significant difference between patients with TSH<60 μIU/mL and those with TSH≥60 μIU/mL (P>0.05). Conclusion The volume of thyroid residue and ablative dose are the main factors for the efficacy of 131I thyroid ablation for DTC. Patients with serum TSH≥30 μIU/mL may have favourable efficacy in thyroid ablation, while excessive serum TSH level may not yield better result.

Key words: differentiated thyroid carcinoma, radioiodine, thyroid remnant ablation, thyroid residue, therapeutic dose